Formulary Changes Update

The following changes to the MPC Approved Drug List (ADL) were approved by the Maryland Physicians Care Pharmacy & Therapeutics Committee. Please review these changes.

| Кеу | | | | | |
|-------------------------------|----------------------------|------------------------|--|--|--|
| UPPER CASE = Brand Name Drugs | Lower case = Generic Drugs | QL = Quantity Limit | | | |
| PA = Prior Authorizations | ST = Step Therapy | AL = Age Limit | | | |
| ADL = Approved Drug List | YOA = Years of Age | DD = Discontinued Drug | | | |

| January 2023 | | | | | | | |
|----------------------|------------------------------|-----------------------|----------------|---------------------------------|--|--|--|
| Drug Name | Therapeutic Class | Change | Effective Date | ADL Alternative (if applicable) | | | |
| Xeljanz & Xeljanz ER | DMARD | Add to formulary w/PA | 01/15/2023 | N/A | | | |
| February 2023 | | | | | | | |
| Drug Name | Therapeutic Class | Change | Effective Date | ADL Alternative (if applicable) | | | |
| Fluticasone HFA | Inhaled corticosteroid (ICS) | Add to formulary | 03/20/2023 | Flovent HFA, Qvar | | | |
| March 2023 | | | | | | | |
| Drug Name | Therapeutic Class | Change | Effective Date | ADL Alternative (if applicable) | | | |
| Flovent HFA | Inhaled corticosteroid (ICS) | Remove from formulary | 06/15/2023 | Fluticasone HFA, Qvar | | | |
| April 2023 | | | | | | | |
| Drug Name | Therapeutic Class | Change | Effective Date | ADL Alternative (if applicable) | | | |

| No Formulary Changes | | | | | | | |
|----------------------|-------------------|-----------------------|----------------|---------------------------------|--|--|--|
| May 2023 | | | | | | | |
| Drug Name | Therapeutic Class | Change | Effective Date | ADL Alternative (if applicable) | | | |
| Amjevita | TNF Inhibitor | Add to formulary w/PA | 05/03/2023 | Adalimumab | | | |